Co-Authors
This is a "connection" page, showing publications co-authored by Giulio Stefanini and Francesco Cannata.
Connection Strength
3.225
-
[Cardiac biomarkers in patients with COVID-19: pragmatic tools in hard times]. Rev Esp Cardiol. 2021 Jul; 74(7):566-568.
Score: 0.932
-
Cardiac biomarkers in patients with COVID-19: pragmatic tools in hard times. Rev Esp Cardiol (Engl Ed). 2021 07; 74(7):566-568.
Score: 0.925
-
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 11 01; 6(6):412-414.
Score: 0.911
-
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020 10; 106(19):1512-1518.
Score: 0.224
-
In-hospital prognostic role of coronary atherosclerotic burden in COVID-19 patients. J Cardiovasc Med (Hagerstown). 2021 11 01; 22(11):818-827.
Score: 0.061
-
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. J Healthc Eng. 2021; 2021:5556207.
Score: 0.060
-
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 10 30; 30(11):1899-1913.
Score: 0.056
-
Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. Circulation. 2020 08 04; 142(5):513-515.
Score: 0.055